Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.

NCT06271252 is registered in ClinicalTrials.gov with OriCell Therapeutics Co., Ltd. as lead sponsor.

NCT NCT06271252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06271252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.
Lead sponsor
OriCell Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
April 3, 2024
Completion date
April 12, 2028
Enrollment
81 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blood protein disorders, cardiovascular diseases, hematologic diseases, hemorrhagic disorders, hemostatic disorders, immune system diseases, immunoproliferative disorders, lymphoproliferative disorders, multiple myeloma, neoplasms, neoplasms by histologic type, neoplasms, plasma cell, paraproteinemias, vascular diseases